Volume 100, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO, 2018. Rapid Communication: Key Changes to Treatment of Multidrug-and Rifampicin-Resistant Tuberculosis (MDR/RR-TB). Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  2. Reuter A et al., 2017. The devil we know: is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis 21: 11141126.
    [Google Scholar]
  3. Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, Rieder HL, 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182: 684692.
    [Google Scholar]
  4. Walsh K, Souroutzidis A, Vilbrun S et al., 2019. Potentially high number of ineffective drugs with the standard shorter-course regimen for multidrug-resistant tuberculosis treatment in Haiti. Am J Trop Med Hyg 100: 392398.
    [Google Scholar]
  5. Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A, 2015. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 19: 517524.
    [Google Scholar]
  6. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A, 2014. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 18: 11881194.
    [Google Scholar]
  7. Schwoebel V, 2018. Risk of Relapse after 9-Month Regimen for Multidrug-Resistant Tuberculosis in Francophone Africa.
    [Google Scholar]
  8. Ahmad Khan F et al., 2017. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J 50: 1700061.
    [Google Scholar]
  9. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017 et al., 2018. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 392: 821834.
    [Google Scholar]
  10. WHO, 2018. Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis Geneva: World Health Organization; 2018. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  11. WHO, 2018. The Use of Next-Generation Sequencing Technologies for the Detection of Mutations Associated with Drug Resistance in Mycobacterium tuberculosis Complex: Technical Guide. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  12. Médecins Sans Frontières (MSF), Partners In Health (PIH), Innovative Research and Development (IRD), 2018. endTB clinical trial. Available at: http://endtb.org/clinical-trial. Accessed December 5, 2018.
    [Google Scholar]
  13. International Union Against Tuberculosis and Lung Disease (IUATLD), 2018. The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients with MDR-TB. Available at: https://clinicaltrials.gov/ct2/show/NCT02409290. Accessed December 5, 2018.
    [Google Scholar]
  • Received : 08 Dec 2018
  • Accepted : 12 Dec 2018
  • Published online : 14 Jan 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error